Skip to content

Trial Summary

This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma.

Acronym:

NUTMEG

ACTRN/NCT /ethics:

ACTRN12617000267358

Scientific title:

A randomised phase II study of nivolumab and temozolomide vs. temozolomide alone in newly diagnosed elderly patients with glioblastoma (NUTMEG)

Sponsor / Cooperative group:

University of Sydney

Trial & Patient Characteristics

Cancer TypeBrain & central nervous system
Trial TypeTreatment
PhasePhase II
Age Range65 and older
SexBoth
Tumour StreamGlioblastoma
Cancer StageAll stages
Anticipated Start Date2018-01-15
Anticipated End Date2019-02-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Hien Le
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting